POSEIDA THERAPEUTICS INC.
History
>
| Year | Detail |
|---|---|
| 2014 | Eric Ostertag founded Poseida in 2014 as a spinout of a genetic engineering company, Transposagen, to revolutionize cell and gene therapeutics by moving away from more traditional, first-generation virus-based approaches. |
| 2018 | Teneobio, Inc., a multi-specific antibody therapeutics company, partnered with Poseida to develop novel CAR-T therapies using Teneobio’s heavy chain-only domain antibodies. |
| 2023 | Astellas and Poseida Therapeutics collaborated to license one of Poseida’s clinical-stage programs: P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy in development for multiple solid tumor indications. |
BCC Research Beacon 